Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.35 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.34 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.34 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.34 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.34 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | GIPR | P48546 | 1/20 | 0.34 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.34 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.34 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.34 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.34 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361549 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL3021166 | 0.91 | — | — | |
| SCHEMBL6360303 | 0.86 | CHRM2 (0.37) | — | |
| SCHEMBL27514912 | 0.86 | — | — | |
| SCHEMBL992260 | 0.86 | — | — | |
| SCHEMBL8905118 | 0.85 | DPP4 (0.33) | — | |
| SCHEMBL8905115 | 0.85 | DPP4 (0.33) | — | |
| SCHEMBL6476990 | 0.84 | — | — | |
| SCHEMBL583649 | 0.84 | — | — | |
| SCHEMBL5965337 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1399433-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002553-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | GCGR 1346/4885ADCY6 3975/4885ADCY3 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.